|
N
|
151 (49.7)
|
153 (50.3)
| |
|
Age (years)
|
67.86 ± 15.74
|
68.19 ± 8.59
|
0.740
|
|
PSA (ng/mL)
|
7.56 (5.40–11.59)
|
6.76 (4.47–10.19)
|
0.074
|
|
Prostate volume (mL)
|
36.55 ± 15.74
|
36.79 ± 16.78
|
0.900
|
|
History of prostate biopsy (n, %)
|
27 (17.9)
|
19 (12.4)
|
0.186
|
|
Positive DRE (n, %)
|
35 (35.7)
|
25 (28.4)
|
0.287
|
|
Prostate cancer detection rate (n, %)
|
95 (62.9)
|
95 (62.1)
|
0.882
|
|
Gleason score
| | |
0.171
|
|
6 (n, %)
|
18 (18.9)
|
26 (27.4)
| |
|
≥ 7 (n, %)
|
77 (81.1)
|
69 (72.6)
| |
|
Pain
| | | |
|
Probe insertion
|
3.39 ± 2.12
|
3.36 ± 2.43
|
0.905
|
|
PNB at base
|
2.91 ± 1.83
|
2.79 ± 1.94
|
0.591
|
|
PNB at apex
| |
4.60 ± 2.50
| |
|
At 15 min post prostate biopsy
|
0.14 ± 0.58
|
0.16 ± 0.74
|
0.749
|
|
Time
| | | |
|
Periprostatic nerve block (min)
|
2.42 ± 0.77
|
2.59 ± 0.88
|
0.084
|
|
Prostate biopsy (min)
|
4.20 ± 2.59
|
4.66 ± 5.41
|
0.343
|
|
Adverse events
| | | |
|
Vasovagal syncope (n, %)
|
2 (1.3)
|
0 (0.0)
|
0.246
|
|
Allergic reaction (n, %)
|
0 (0.0)
|
0 (0.0)
|
–
|
|
AUR (n, %)
|
0 (0.0)
|
0 (0.0)
|
–
|
|
Urinary retention because of blood clot (n, %)
|
0 (0.0)
|
0 (0.0)
|
–
|
|
Fever (n, %)
|
0 (0.0)
|
0 (0.0)
|
–
|
